ArticleBMC infectious diseases2026
In vitro activity of eight antifungal drugs against clinical and hospital isolates of Candida parapsilosis complex; a multicenter study, 2023-2024.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundCandida parapsilosis complex is an emerging opportunistic pathogen associated with bloodstream infections and healthcare‑associated outbreaks, particularly in intensive care units. Rising antifungal resistance underscores the need for continuous surveillance. This multicenter study assessed the in vitro susceptibility of eight antifungal agents against clinical, environmental, and healthcare worker isolates of the C. parapsilosis complex and investigated potential molecular mechanisms of resistance.
methodsA total of 2,600 samples were collected between May 2023 and December 2024, including 2,180 clinical specimens, 330 environmental samples, and 90 hand swabs from healthcare workers. From these, 527 C. parapsilosis isolates were recovered. Identification was performed using conventional and molecular approaches. Antifungal susceptibility testing followed CLSI M27 (4th edition) guidelines. Isolates exhibiting resistance were further analyzed by sequencing the ERG11 and FKS1 genes.
resultsAmong the 527 isolates, 510 originated from clinical settings, 6 from reusable breast pump sets, and 11 from healthcare worker hands. Overall, 10 isolates (1.9%) demonstrated resistance according to CLSI breakpoints, all of which were clinical in origin. Resistance was detected to fluconazole (0.38%), caspofungin (0.95%), and combined caspofungin-anidulafungin resistance (0.57%). The MIC values for fluconazole and caspofunginwere 4 µg/mL, indicating reduced susceptibility among clinical isolates. Voriconazole, clotrimazole, and amphotericin B exhibited strong in vitro activity. No resistance‑associatedmutations were identified in ERG11 or FKS1.
conclusionsDespite the absence of detectable ERG11 or FKS1 mutations, reduced susceptibility to azoles and echinocandins was observed, primarily among clinical isolates. Environmental and healthcare worker isolates showed lower MIC values, suggesting minimal antifungal selection pressure outside patient care environments. These findings point to emerging antifungal resistance in C. parapsilosis clinical isolates in Iran and emphasize the importance of ongoing surveillance and molecular monitoring to inform therapeutic and infection control strategies. However more studies are required to correlate these findings with clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.